Compare Crispr Therapeutics AG (CRSP) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Alphabet Inc Class A — how do they compare? Crispr Therapeutics AG trades at $50.88 (market cap $4.97B), while Alphabet Inc Class A trades at $372.14 (market cap $4.37T). The key difference: Alphabet Inc Class A is far larger — about 879.3× Crispr Therapeutics AG's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | GOOGL | |
|---|---|---|
Market Cap | $4.97B | $4.37T |
Sector | Health | Media |
52-Week High | $76.78 | $402.62 |
52-Week Low | $44.34 | $182.00 |
Enterprise Value | $3.32B | $4.34T |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Alphabet (GOOGL) trades at $370.92, up 5.22% with strong fundamental performance including 32.8% net income margin and consistent earnings beats. Technical indicators show neutral momentum with support at $355 and resistance at $362. The company demonstrates robust revenue growth from $350B in 2024 to $402.8B in 2025, supported by AI-driven advertising expansion and cloud services.
Outlook remains positive with 85% analyst buy ratings and $431.78 consensus target, representing 16% upside. Key risks include antitrust scrutiny and AI competition, but strong cash flow generation and YouTube subscription pricing increases provide stability. The stock offers growth exposure to AI infrastructure and digital advertising leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
